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Abdominal aortic aneurysm (AAA) is a significant cause of mortality in older adults. A key 36 
mechanism implicated in AAA pathogenesis is inflammation and the associated production of 37 
reactive oxygen species (ROS) and oxidative stress. These have been suggested to promote 38 
degradation of the extracellular matrix and vascular smooth muscle apoptosis. Experimental and 39 
human association studies suggest that ROS can be favourably modified to limit AAA formation and 40 
progression. In this article, we discuss mechanisms potentially linking ROS to AAA pathogenesis and 41 
highlight potential treatment strategies targeting ROS. Currently, none of these strategies have been 42 



























Abdominal aortic aneurysm (AAA) is a degenerative disease of the aorta common in people aged > 68 
65 years.(1, 2)  AAA is usually asymptomatic until rupture which is frequently fatal.(1-4) However, 69 
rupture of small AAAs is rare.(5)  The main focus of AAA management is to prevent rupture, 70 
therefore current guidelines recommend that patients with large AAAs (>5-5.5cm) undergo 71 
endovascular stent graft or open surgical repair.(4, 6) Patients with small AAAs undergo regular 72 
imaging to monitor AAA diameter, although up to 70% of these individuals eventually require AAA 73 
repair.(2) 74 
AAA is believed to result from an aberrant interaction between genetic factors and the environment 75 
which aggravates the normal ageing processes.(1, 2)  One of the key features of AAA is vascular wall 76 
inflammation associated with significant production of reactive oxygen species (ROS).(3, 6)  ROS, 77 
which include hydrogen peroxide (H2O2), superoxide (O2−), and hydroxyl radical (•OH) are oxygen-78 
derived chemical molecules with high reactivity.(7, 8) Reports from recent clinical and experimental 79 
investigations suggest that oxidative stress, i.e. production of ROS in excess of antioxidant protection, 80 
is involved in the vascular degeneration found in AAA.(9-11) Imbalance in the activity of endogenous 81 
pro-oxidative enzymes such as nicotinamide adenine dinucleotide phosphate oxidase (NOX) and 82 
xanthine oxidase (XO), the mitochondrial respiratory chain and the antioxidant enzymes such as 83 
glutathione peroxidase, heme oxygenase (HO), superoxide dismutase (SOD), thioredoxin (TRX), and 84 
catalase results in excessive ROS.(12, 13)  This is implicated in vascular cell dysfunction, lipid and 85 
protein peroxidation, and deoxyribonucleic acid (DNA) damage which can result in permanent 86 
cellular damage and death.(7, 12, 13) ROS regulate the degradation and remodelling of the 87 
extracellular matrix (ECM) by upregulating proteolytic enzymes such as matrix metalloproteinases 88 
(MMPs), (14) activating signalling kinases and transcription factors such as nuclear factor kappa beta 89 
(NF-κB) and activator protein 1 (AP-1),(15-17) and promoting vascular smooth muscle cell (VSMC) 90 
apoptosis.(18, 19) ROS also regulate fibroblast proliferation and macrophage and mononuclear 91 
lymphocyte infiltration.(7, 20, 21)  92 
In this article we discuss mechanisms potentially linking ROS to AAA pathogenesis and review 93 
potential treatment strategies targeting ROS in the management of AAA based on experimental and 94 
human studies.  95 
 96 
Literature Search 97 
A literature search was conducted to identify studies assessing antioxidants as therapeutic targets for 98 
AAA using the Embase (1980), MEDLINE (1966), SCOPUS (1996), Web of Science (1965), and 99 
Cochrane Library databases (1992) from inception to the 25th of May, 2015. The following search 100 
terms were applied either as single or combined searches: “abdominal aortic aneurysm” OR “AAA”, 101 
[Title/Abstract] AND “antioxidant treatment” OR “antioxidant targets” OR “antioxidant therapy”, 102 
AND/OR “clinical studies” OR “human studies”, AND/OR “animal studies” OR “experimental 103 
studies”. Abstracts were analysed for relevance and studies describing the therapeutic potential of 104 
antioxidants in AAA pathogenesis were retrieved. Human and animal studies investigating the 105 
therapeutic potential of antioxidants in AAA were included. Included article references were hand 106 
searched for relevant publications meeting the inclusion criteria. Studies excluded include those in 107 




Evidence linking ROS with AAA 110 
ROS such as NO and O2− are produced by all vascular cell types principally via membrane-associated-111 
specific enzymes such as NOX, XO, and nitric oxide synthase (NOS). (7, 13) Both animal and human 112 
studies have associated elevated concentrations of ROS, or surrogate markers of ROS with AAA. (11, 113 
22-24) 114 
 115 
Animal studies 116 
Evidence from different animal models implicates ROS in AAA pathogenesis. Nakahashi and 117 
colleagues reported that HO-1 expression was significantly upregulated within the elastase-induced 118 
rat model of AAA. (24) They further demonstrated the localisation of HO-1 to infiltrative 119 
macrophages within the aneurysmal aortic wall. Similarly, iNOS produced NO has been reported to 120 
exacerbate experimental AAA development.(25) Lizarbe et al. reported a reduction in aortic diameter 121 
and MMP-13 expression in mice administered the iNOS inhibitior, 1400 W.(14) In the angiotensin II 122 
(AngII)-induced mouse model of AAA, 8-isoprostane,(23) and 8-hydroxy-2' -deoxyguanosine (8-123 
OHdG), (9) concentrations  (markers of oxidative stress) have been reported to be high within the 124 
aneurysmal aorta. Similarly, high 8-OHdG content and glutathione peroxidase expression were 125 
reported within the calcium chloride (CaCl2)-induced mouse model of AAA. (26) Infiltrating 126 
inflammatory cells and their products have been reported to be involved in aortic wall degradation and 127 
ensuing AAA formation.(3, 27) (28)  128 
 129 
Human associated studies 130 
Dubick and colleagues reported low levels  of vitamin C, and lower copper-zinc SOD (CuZnSOD) 131 
activity in aortic tissue samples from 29 patients with AAA and 14 patients with atherosclerotic 132 
occlusive disease (AOD) compared to non-diseased control aortas.(29) SOD is a family of 133 
metalloenzymes including CuZnSOD, manganese SOD (MnSOD), and extracellular SOD (EcSOD) 134 
that catalyses the dismutation of O2− into oxygen and H2O2 thereby maintaining vascular NO 135 
concentrations.(30, 31)   High MnSOD and low CuZnSOD activities were observed in a study 136 
evaluating the effect of hypertension on aortic antioxidant status in human AAA and AOD.(42) In 137 
contrast, a separate study suggested that both CuZnSOD and MnSOD activities were lower in infra-138 
renal aortic biopsies collected from patients with intact and ruptured AAAs compared to non-139 
aneurysmal organ donors.(32) This study also suggested that glutathione reductase and glutathione 140 
peroxidase were downregulated whilst lipid peroxidation products were high in AAA patients, 141 
particularly those with ruptured aneurysms, compared to controls.(32) Aberrant lipid peroxidation has 142 
been associated with aortic cell apoptosis and necrosis, (discussed in (33, 34)) which potentially 143 
promotes aortic weakening and AAA. Evidence also suggests that dysregulated antioxidant protective 144 
mechanisms,(35-42) and/or low levels of exogenous antioxidants (vitamin C, vitamin E) can 145 
exacerbate ROS activity.(7, 13, 43) In addition, Miller et al. reported high expression of O2− and NOX 146 
activity in biopsies of human aneurysmal aortas compared with biopsies from adjacent non-147 
aneurysmal aortas.(11) Zhang et al. reported high iNOS expression in the media and adventitia of 148 
human AAA tissues compared to controls.(44) They suggested that iNOS promotes AAA progression 149 
by selectively stimulating the formation and activity of the NO-derived oxidant peroxynitrite (ONOO-150 
) with consequent aortic oxidative injury and AAA.(44)  151 
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Collectively, these studies suggest that oxidative stress is associated with the presence of AAA. It 152 
remains to be shown whether targeting ROS or their modulators would be an effective strategy in 153 
managing AAA. 154 
 155 
Potential mechanisms linking oxidative stress with AAA and associated therapeutic targets  156 
Sies defined oxidative stress as an imbalance between ROS and antioxidants in favour of the oxidants 157 
leading to cellular injury and damage.(45) There is a close association between oxidative stress and 158 
inflammation as evidence suggests that oxidative stress induces inflammation, which in turn 159 
potentiates oxidative stress with resultant injury to tissues.(11, 46, 47) The human body is equipped to 160 
maintain the oxidant-antioxidant balance to avoid injury in physiological conditions, but potentially 161 
not in pathophysiological conditions like AAA (discussed in (45, 48)).  162 
A number of endogenous enzyme systems regulating oxidative stress in AAA have been researched in 163 
both pre-clinical and clinical studies in the past decade (Figure 1). The following sections summarise 164 
the potential mechanisms linking these pathways to AAA and strategies which potentially, may be 165 
used therapeutically to limit AAA (Figure 2). 166 
 167 
Xanthine and NADPH oxidases 168 
NOX activity has been reported to be markedly elevated by stimuli thought to be key in the 169 
pathogenesis of AAA such as Ang II, TNF-α, mechanical stretch, and endothelin-1 acting both 170 
through transcriptional pathways and posttranslational modification of oxidase regulatory subunits.(7, 171 
49)   Ang II for example, has been reported to induce mitochondrial dysfunction via a protein kinase 172 
C–dependent pathway by activating NOX and forming NO, ONOO-, and O2− (Figure 2).(50) 173 
Oxidative stress has been reported to enhance expression of angiotensin converting enzyme (ACE) 174 
which is responsible for the conversion of angiotensin I (Ang I) to Ang II.(51)  In addition, mice 175 
overexpressing the NOX catalytic subunit Nox1 within VSMC are reported to have an enhanced 176 
response to Ang II, exhibit increased O2− and H2O2 production and have aortic thickening.(52, 53)  177 
Thomas et al. employing the Ang II-infused mouse model of AAA reported that deletion of p47phox, 178 
a cytosolic subunit of NOX, abrogated NOX activity, reduced production of ROS within the aorta and 179 
within infiltrating leukocytes, and significantly reduced the incidence and progression of AAA.(54) In 180 
contrast, inhibition of Nox1 has been associated with resistance to aortic dissection and AAA 181 
development in mouse models.(55)  However, a deficiency in another NOX catalytic subunit, Nox2 182 
was reported to exacerbate Ang II-induced AAA in mice and promote interleukin-1 beta (IL-1β) and 183 
MMP-9 expression.(56) Inhibition of IL-1β or IL-1β receptor expression has been reported to confer 184 
AAA resistance in mouse models.(57)  185 
XO is also a H2O2 and O2− generating enzyme formed from the proteolytic breakdown of xanthine 186 
dehydrogenase.(13) Experimental evidence suggests XO is expressed by aortic endothelial cells in a 187 
NOX dependent manner,(58) and is actively involved in lipid peroxidation and damage to the ECM 188 
(discussed in (59)). However there are limited studies investigating the specific role of XO in AAA 189 
pathogenesis. 190 
Taken together, these studies suggest a potential mechanism by which NOX may modulate AAA 191 
pathogenesis via effects on the renin-angiotensin system (RAS), inflammatory cytokines and MMPs. 192 
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Zhang et al. reported that cilostazol, a phosphodiesterase III inhibitor that selectively targets cyclic 193 
adenosine monophosphate (cAMP), inhibited AAA development in an elastase-induced rat model. 194 
(60) Cilostazol is a 2-oxo-quinoline derivative with antithrombotic, vasodilator, antimitogenic and 195 
cardiotonic properties and is indicated for intermittent claudication in patients with peripheral arterial 196 
disease.(61) Cilostazol was shown to significantly reduce NOX activity and ROS concentration with 197 
consequent inhibition of MMP-2 and MMP-9 expression, and NF-κB activation (P < 0.05).(60) In a 198 
CaCl2 mouse model of AAA, mice orally administered apocynin (a NOX inhibitor) were shown to 199 
have reduced MMP-2, MMP-9 and NO metabolite (NO2 and NO3) expression within aortic tissues, 200 
and decreased aneurysm formation compared to controls.(18) In contrast, Kigawa et al. reported that 201 
mice deficient in NOX demonstrated increased incidence of AAA, albeit with decreased ROS 202 
expression, within an Ang II-induced low-density lipoprotein receptor knock-out (Ldlr-/-) mouse 203 
model of AAA.(56) Collectively, these studies suggest that medication targeting both NOX and XO 204 
pathways may limit AAA formation and progression, although more studies are needed to validate 205 
these findings. 206 
 207 
Lipoxygenases 208 
Lipoxygenases are non-heme iron–containing enzymes that catalyse the stereospecific deoxygenation 209 
of polyunsaturated fatty acids with a 1, 4-cis, cis-pentadiene structure (62, 63) and are also proficient 210 
in the generation of ROS, or augmenting leukocyte ROS production.(8, 64) Lipoxygenases are 211 
required for the biosynthesis of leukotrienes, which are key inflammatory and chemotactic 212 
mediators.(65) For example, inhibition of lipoxygenases including 5- lipoxygenase (5-LO) has been 213 
reported to reduce the expression of MMP-2 and -9, and phagocytic macrophage infiltration.(66-68)  214 
The proteolytic breakdown of the ECM by MMPs has been reported to be one of the key mechanism 215 
involved in AAA pathogenesis (for a detailed review of MMPs and AAA, please see (69)). It has been 216 
suggested that by promoting inflammation and the proteolytic degradation of the ECM via effects on 217 
MMPs expression and recruitment of inflammatory cells, lipoxygenases may play a role in inducing 218 
AAA formation. 219 
A growing body of evidence has implicated lipoxygenases in the pathogenesis of AAA as illustrated 220 
in Table 1.(46, 66, 67) A recent study by Bhamidipati et al. using an elastase perfused- and an Ang II-221 
infused Ldlr-/- mouse models of AAA demonstrated that 5- lipoxygenase (5-LO) inhibition attenuated 222 
AAA formation and progression.(67) The authors reported that genetic deletion of 5-LO within the 223 
elastase infused mouse model resulted in a 71% reduction in aortic dilatation compared with wild-224 
type controls. Mice administered 30 mg/kg/day of AZD4407 (a selective 5-LO inhibitor) were also 225 
shown to be resistant to AAA formation and progression associated with decreased MMP-9 enzymatic 226 
activity and immune cell infiltration within aortic tissue. These findings were further strengthened 227 
through studies within the Ang II-infused Ldlr-/-mouse model of AAA, were they reported that 228 
administration of AZD4407 within the chow for 28 days inhibited 5-LO activity within the circulation 229 
resulting in a 54% reduction in aneurysm formation compared to control.(67) 230 
Edaravone (3-methyl-1-phenyl-2-pyrazoline-5-one), a powerful antioxidant indicated as a therapeutic 231 
agent for acute cerebral infarction,(70) was reported to significantly reduce the expression of MMP-2, 232 
MMP-9 and ROS, and abrogate AAA formation and expansion in the combined elastase-induced and 233 
CaCl2-induced rat model of AAA.(71) In addition, earlier studies by Zhao et al. found that ApoE–/– 234 
mice lacking 5-LO genes and fed a cholic acid-rich diet demonstrated a reduced incidence of 235 
AAA.(66)  Consistent with this, Ang II-infused ApoE–/– mice deficient in leukotriene B4 receptor 1 236 
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(BLT1) were shown to exhibit decreased incidence and size of AAA.(72) In a similar model, a BLT 237 
antagonist (CP-105,696) limited AAA formation when administered at the same time as Ang II 238 
infusion, but did not limit progression of established aneurysms. (68). Cao et al. employing the Ang 239 
II-infused ApoE–/– mouse model of AAA, reported that mice deficient in 5-LO or administered a 5-LO 240 
activating protein (FLAP) inhibitor (MK-0591) had a similar incidence of AAA development to 241 
controls.(73)  242 
A human association study reported higher expressions of leukotriene C4 synthase (LTC4S), 5-LO 243 
and FLAP within aneurysmal aortas compared to non-aneurysmal donor aortas.(74) Others have also 244 
reported high production of leukotriene B4 (LTB4) by polymorphonuclear leukocytes localised within 245 
intra-luminal thrombus samples collected from patients undergoing aneurysm repair.(75) A study 246 
involving 613 men aged ≥65 with AAA and 707 randomly selected age-matched controls failed to 247 
find an association between 7 single nucleotide polymorphisms in ALOX5AP, the gene encoding 248 
FLAP, with human AAA.(76) Together, these reports fail to show a consistent role of lipoxygenase in 249 
human and experimental AAA. 250 
 251 
Cyclooxygenases 252 
Cyclooxygenases (COX) are the key enzymes involved in the conversion of arachidonic acid to 253 
prostaglandins.(77) It has been reported that COX-2 and its metabolite, prostaglandin E2 (PGE2), are 254 
highly expressed within aneurysmal tissue and exacerbate VSMC apoptosis.(78-80)  COX-2 255 
expression was also reported to be associated with increased macrophage infiltration,(81) and 256 
increased MMP-2 expression and aortic remodelling. Collectively, this information suggests that 257 
COX-2 may play a significant role in AAA pathogenesis via effects on VSMC integrity and 258 
inflammation, stimulating interest in treatments targeting the COX pathway as a means of limiting 259 
AAA. Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), and a selective COX-2 inhibitor, 260 
was reported to reduce the incidence and severity of AAA within the Ang II-induced mouse model in 261 
both hyperlipidaemic and nonhyperlipidaemic mice.(82) In the same mouse model of AAA, Gitlin et 262 
al. reported that mice with genetic deletion of COX-2 failed to develop AAA. They reported a 73% 263 
and 90% reduction in AAA incidence following 7 and 21 days of Ang II infusion respectively and a 264 
marked decrease in the aortic expression of the macrophage marker CD68, MCP-1 and macrophage 265 
inflammatory protein-1alpha (MIP-1α).(81) This is in contrast to the study by Cao et al. reporting that 266 
genetic deletion of COX-2 had no significant effect on AAA development within the Ang II-induced 267 
AAA mouse model.(83) However, two recent studies provide evidence that mice administered 268 
celecoxib have decreased AAA progression and rupture within the Ang II infused mouse model of 269 
AAA.(84, 85) Another selective COX-2 inhibitor, MF-tricyclic, was reported to inhibit MMP-9 270 
expression and consequently AAA growth within an elastase-induced rat model of AAA.(86) In 271 
support, two other studies employing the same elastase-induced rat model of AAA reported that 272 
indomethacin (a non- selective COX-2 inhibitor) significantly inhibited PGE2 and MMP-9 expression 273 
thereby preserving elastin integrity and reducing AAA expansion with no effect on the inflammatory 274 
infiltrate.(87, 88) Conversely, Armstrong and colleagues reported that indomethacin and rofecoxib (a 275 
selective COX-2 inhibitor) failed to impede aneurysm expansion within the elastase-induced AAA rat 276 
model.(89) Furthermore, in a small case-control study involving 15 subjects on NSAIDs and 63 277 
patients without NSAID, it was reported that AAA growth was significantly reduced in patients 278 
receiving NSAIDs compared to controls without NSAIDs.(80) COX inhibitors have been associated 279 
with increased incidence of cardiovascular events (myocardial infarction stroke and cardiovascular 280 
death), and it is therefore unclear whether they would be safe to give patients with AAA.(90, 91) The 281 
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conflicting evidence from experimental studies regarding their therapeutic potential does not currently 282 
support their trialling in AAA patients. A summary of studies investigating the role of COX in AAA 283 
pathogenesis is given in Table 2. 284 
 285 
Nitric oxide synthases 286 
The family of NOS including inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS 287 
(nNOS) are capable of generating NO and L-citrulline by catalysing the oxidation of L-arginine. Both 288 
eNOS and nNOS are selectively expressed whereas iNOS is widely distributed within multiple cell 289 
types.(12, 92) NO is an important regulator of cardiovascular homeostasis, however evidence suggest 290 
that under specific conditions, exaggerated production of NO by iNOS may lead to tissue damage 291 
through several mechanisms including the formation of reactive nitrogen species.(93) In addition, 292 
uncoupling of eNOS from its cofactors is associated with increased generation of O2−,(93, 94) and 293 
consequent tissue damage which has been suggested to be relevant in AAA pathogenesis.(94, 95)  294 
A number of medications which were not developed to modulate NOS have been suggested to have 295 
pleiotropic effects on NOS which in part explain their ability to limit AAA within experimental 296 
models (Table 3). For example a number of studies suggest that statin therapy may limit AAA 297 
development due to its antioxidant and anti-inflammatory effects.(96-102) In an elastase induced rat 298 
model of AAA, Kalyanasundaram et al. reported that simvastatin administration resulted in the 299 
downregulation of several oxidative stress-related genes including SOD2, HO-1, NOS3 and 300 
thioredoxin reductase 1 (TRXR1) with consequent AAA inhibition.(96) Simvastatin was also shown 301 
to reduce NF-κB, MMP-9 and MMP3 expression.(96) This is supported by the study by Steinmetz et 302 
al. which demonstrated that simvastatin inhibited AAA formation independent of serum cholesterol 303 
levels in the C57BL/6 wild type and the ApoE-/- mice using the elastase-infused mice model of 304 
AAA.(97) They reported a simvastatin-mediated decrease in MMP-9 and increase in TIMP-1 305 
expression, but did not measure any ROS.(97) In contrast, others have reported that simvastatin had 306 
no significant effect on aortic diameter within the Ang II-induced mouse model of AAA.(103) In two 307 
previous studies, fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) activator 308 
used clinically to reduce triglycerides, was shown to abrogate Ang II-induced AAA within Ldlr-/- and 309 
ApoE-/- mice.(104, 105) Fenofibrate upregulated eNOS within the tunica intima and iNOS within the 310 
tunica media and adventitia associated with reduced Ang II induced AAA formation.(105) In addition, 311 
within a CaCl2 mouse model of AAA, iNOS deficient mice were shown to be partly resistant to AAA 312 
formation associated with decreased MMP-2, MMP-9 and NO expression within aortic tissues.(18)   313 
In contrast, Gao et al. reported that mice deficient in the eNOS cofactor tetrahydrobiopterin (H4B) 314 
were prone to Ang II-induced AAA formation.(94) They reported that oral folic acid treatment 315 
upregulates the expression and activity of the H4B salvage enzyme dihydrofolate reductase within the 316 
endothelium, restores eNOS function and inhibited AAA formation.(94)  In a further study employing 317 
the Ang II infused ApoE-/- mice model of AAA, Siu and colleagues also demonstrated that oral 318 
administration of folic acid limited aortic elastin degradation, macrophage infiltration and 319 
significantly inhibited AAA expansion by upregulating eNOS activity.(95) Similarly, deletion of the 320 
eNOS gene within ApoE-/- mice has been associated with increased AAA formation.(106) These 321 
studies suggest that due to the complexity of these enzymes, the underlying difference in the animal 322 
models involved, and the inconsistent findings it is currently unclear how NOS regulation is involved 323 




Heme oxygenases and thioredoxin 326 
HO-1 is an enzyme that reduces oxidative stress by catalysing heme to carbon monoxide, biliverdin, 327 
bilirubin, and free ferrous iron.(12, 13, 107, 108) The endogenously produced carbon monoxide is 328 
reported to serve as a second messenger influencing cellular proliferation, inflammation, and 329 
apoptosis.(109)  330 
Nakahashi et al. were the first to suggest that HO-1 may be beneficial in limiting AAA 331 
development.(24) The authors conducted a microarray analysis to investigate aortic gene expression 332 
following a femoral arteriovenous fistula to increase laminar shear and wall strain within an elastase-333 
induced rat model of AAA. They found that flow loading decreased AAA diameter and upregulated 334 
HO-1 expression.(24) 335 
Two contradictory case-control studies were found examining the relationship between the HO-1 gene 336 
promoter region and AAA prevalence in humans.(110, 111) Short (<25 GT) dinucleotide repeats 337 
within the HO-1 gene promoter region are associated with greater HO-1 expression whilst longer (≥25 338 
GT) dinucleotide repeats are associated with lower HO-1 expression in response to recognised 339 
stimuli. (112) A study by Schillinger and colleagues suggested that patients with AAA were less 340 
frequently carriers of short (< 25 GT) repeats within the HO-1 gene promoter compared to 341 
atherosclerotic or healthy controls. The findings suggested that short (<25 GT) dinucleotide repeats 342 
within the HO-1 gene promoter region associated with increased HO-1 expression protected against 343 
AAA.(110) In contrast, a more recent study by Gregorek et al. found more short (< 25 GT) repeats 344 
within the HO-1 gene promoter alleles in AAA patients compared to healthy non-aneurysmal 345 
controls.(111) Both studies have limitations that may have influenced the results, such as, the small 346 
sample sizes (70 AAA patients in the study of Schillinger et al. and 117 in the investigation of 347 
Gregorek and colleagues), the relatively wide 95 % confidence interval in both studies, and lack of 348 
validation of findings. Therefore, it remains to be seen what role HO-1 plays in AAA formation and 349 
progression. 350 
Thioredoxin (TRX) is a thiol oxidoreductase and regulator of signal transduction found in endothelial 351 
cells and VSMC.(41) Functionally, TRX has been suggested to modulate NOX-mediated generation 352 
of O2− via interaction with p40Phox,(113) and to decrease IL-1β expression by monocyte-derived 353 
macrophages during inflammation.(114) These effects are potentially partly mediated by 354 
downregulating macrophage inhibitory factor (MIF).(115)  355 
Only one study was found investigating TRX in AAA patients.(22) In a multicentre cohort study, the 356 
authors reported that TRX was present at higher concentrations in the serum of patients with AAA 357 
and concentrations were correlated with AAA diameter and growth rate.(22) More investigations into 358 
the importance of TRX in AAA using experimental and human association studies are needed to 359 
further elucidate the role of TRX.  360 
 361 
Superoxide dismutases and catalases 362 
The efficacy of the SOD system has been reported to rely on the ability of catalase or glutathione 363 
peroxidase to subsequently catalyse the decomposition of H2O2 to water and oxygen, and inhibit the 364 
conversion of H2O2 to the •OH.(13) H2O2 has been reported to promote MMP-3, MMP-9 and MMP-12 365 
expression,(116) which have been implicated in ECM degradation important in AAA. The ability of 366 
the SOD system to balance H2O2 levels could be important in protecting against AAA. 367 
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Catalase is an enzyme responsible for the degradation of H2O2 to water and oxygen and has 368 
cardiovascular protective effects,(117) including inhibition of Ang II-induced aortic thickening.(37) 369 
Patients with AAA have been reported to have low catalase expression within circulating neutrophils 370 
and plasma.(118) Catalase has been reported to abrogate the H2O2-mediated increases in MMP 371 
expression and inflammatory cytokine secretion. (117, 119)  372 
Several studies have investigated the relationship between SOD, catalases and AAA as shown in 373 
Table 4.(119-124)  In a study, employing an elastase-induced rat model of AAA, Sinha et al. reported 374 
a significant increase in MnSOD levels and MMP-9 activity in aneurysmal aortas during the early 375 
stages of aneurysm formation. CuZnSOD and EcSOD levels were similar in AAAs and control 376 
aortas.(120) The authors reported that a SOD mimetic, TEMPOL, increased MMP-2 and MMP-9 377 
activity by more than 2-fold in aortic explant cultures, and suggested that strategies aimed at 378 
inhibiting oxidative stress during AAA formation should focus on MnSOD.(120) In a recent study 379 
employing the CaCl2 induced mouse model of AAA, a standardised extract from Ginkgo biloba, EGb 380 
761, reported to possess antioxidant and free radical scavenging properties,(125) was shown to 381 
significantly reduce NF-κβ protein expression, MMP-2 and MMP-9 activities within the aorta, inhibit 382 
SOD and catalase activity, and decrease aneurysm size.(126) Other studies however report that 383 
increased SOD is beneficial against AAA formation.(121) For example, another natural product, 384 
diferuloylmethane (curcumin), a phenol found in the dietary spice turmeric,(127) has been reported to 385 
exert anti-inflammatory effects via inhibition of ROS production and enhanced SOD expression.(121)  386 
Curcumin was also reported to inhibit aneurysm formation.(128)  An initial study using the elastase-387 
induced mouse model of AAA showed that curcumin inhibited AAA formation by decreasing aortic 388 
inflammation and MMP-9 expression.(129) Similarly, in the Ang II-induced mouse model of AAA, 389 
Hao et al. reported that oral administration of curcumin significantly decreased aortic macrophage 390 
infiltration, MCP-1 and TNF-α concentrations and AAA incidence, and increased SOD activity.(121)  391 
Cobalt chloride (CoCl2), an inhibitor of the hypoxia-inducible factor alpha (HIF-1α) degrading prolyl 392 
hydroxylase domain protein,(130) was reported to restore SOD and catalase expression within a 393 
CaCl2 model of AAA, and inhibit NF-κβ phosphorylation, cytokine expression and consequent AAA 394 
formation.(123) Taken together, there is no consistent evidence on the role of SOD in AAA 395 
pathogenesis.  396 
A study examining the effect of tamoxifen, a selective oestrogen receptor modulator with potent 397 
antioxidant and vasodilator properties,(131) demonstrated that rats receiving 10mg/kg/day of 398 
tamoxifen subcutaneously exhibited a marked increase in aortic catalase expression associated with 399 
significant inhibition of neutrophil infiltration and AAA expansion compared to controls within the 400 
elastase-induced rat model of AAA.(124) The direct irreversible catalase inhibitor 3-amino-1, 2, 4-401 
triazole (AT) was shown to significantly abrogate the aneurysm inhibitory effect of tamoxifen by 402 
roughly 30%.(124) In addition, transgenic ApoE-/- mice overexpressing the human catalase gene 403 
within VSMC where shown to be resistant to Ang II induced aortic wall remodelling thought to be 404 
involved in early AAA formation.(132) This finding was supported by a similar study within the 405 
CaCl2 induced mice model of AAA, where both transgenic mice over expressing catalase and mice 406 
administered polyethylene glycol-catalase (PEG-catalase) where shown to exhibit decreased MMP 407 
activity, decreased VSMC apoptosis and decreased AAA formation.(119) However, mice transgenic 408 
for catalase did not have altered H2O2 concentrations.(119) These studies suggest that upregulating 409 





Studies investigating exogenous and phenolic antioxidants  413 
Exogenous antioxidants including folic acid, vitamin C (ascorbic acid), and vitamin E (α-Tocopherol) 414 
are reported to modulate ROS production with implications for AAA pathogenesis.(23, 133-136) For 415 
example, vitamin E which has been reported to also inhibit COX expression,(133) has been shown to 416 
inhibit AAA formation in two different rodent models of AAA.(23, 24, 137) In the Ang II-induced 417 
ApoE-/- mice model of AAA, Gavrila et al. reported decreased concentrations of markers of oxidative 418 
stress and aortic macrophage infiltration along with reduction in maximum AAA diameter and 419 
incidence of rupture in mice receiving vitamin E.(23) Gopal et al. reported that dietary 420 
supplementation with vitamin E and β-carotene confers substantial protection against Ang II induced 421 
AAA formation. (137) In an elastase-induced rat model of AAA, Nakahashi and colleagues reported 422 
that rats receiving vitamin E had significantly decreased AAA expansion compared to controls.(24) 423 
Unfortunately in a randomised double-blind placebo-controlled trial, Tornwall et al. failed to show 424 
any significant association between vitamin E supplementation and the incidence of AAA.(138) The 425 
latter study did not include aortic imaging and simply relied on the clinical presentation of AAA. This 426 
study does not therefore rule out a benefit of vitamin E in limiting AAA growth. 427 
Vitamin C is considered to be one of the most efficient water-soluble antioxidant in human plasma 428 
with the ability to scavenge ROS, regenerate α-tocopherol and reduce H4B preventing eNOS 429 
uncoupling.(12, 43, 139) Shang et al. in a study using the elastase-induced rat model of AAA 430 
demonstrated that daily intraperitoneal injection of vitamin C (100mg/ml) significantly decreased 8-431 
hydroxylguanine and 8-isoprostane (markers of oxidative stress), MMP-2, MMP-9 and IL-1β 432 
expression, upregulated TIMP-1 and -2 expression and abrogated AAA expansion by 26%.(10) In a 433 
similar study employing the combined elastase and CaCl2-induced rat model, vitamin C 434 
administration was shown to limit AAA formation through downregulation of MMP-9, MCP-1, IL-435 
1β, TNFα, CD68, and ROS (8-hydroxylguanine).(140) 436 
Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a dietary polyphenol commonly found in red wine and 437 
grape skin with antioxidant,(141-144) anti-inflammatory,(145) and anti-angiogenic(146) effects has 438 
been reported to inhibit experimental AAA.(26, 147)  In a CaCl2 induced mice model of AAA, 439 
resveratrol (at 100mg/kg/day) was reported to prevent AAA development by attenuating the 440 
expression of glutathione peroxidase, MCP-1, TNF-α and CD68 and reducing the activity of MMP-9 441 
and -2.(26)  One limitation of this study was the effect of resveratrol at other doses or time points was 442 
not reported especially since 100mg/kg/day is quite a large dose within mice. Palmieri et al. studied 443 
the effect of resveratrol within the elastase-induced rat model of AAA.(147) They reported that male 444 
Sprague-Dawley rats receiving 10 mg/kg/day resveratrol one week before until two weeks following 445 
AAA induction exhibited significantly decreased CD62L-monocyte subset expansion, CD143 446 
monocyte expression, TNFα expression and MMP-9 activity with consequent inhibition of AAA 447 
development.(147) In addition, the polyphenolic flavonoid quercetin, which has antioxidant and anti-448 
inflammatory properties,(148) was reported to reduce the aortic expression of MMP-2, MMP-9, and 449 
cathepsin, and limit macrophage infiltration with consequent decrease in AAA diameter.(149) In a 450 
second experiment, the authors reported the inhibitory effects of quercetin on AAA incidence via 451 
attenuation of oxidative stress and MMP activation was in part through the modulation of c‑Jun N‑452 





The potential of modulating oxidative stress to limit AAA growth in patients 456 
The studies noted above provide good evidence that markers of oxidative stress are upregulated in 457 
experimental and human AAA. The wide range of oxidative stress pathways upregulated and the 458 
number of interactions between these makes it extremely complex to design interventions which can 459 
effectively reduce aortic oxidate stress long-term (see Figure 2). This is particularly difficult where 460 
high levels of oxidative stress are already present such as within established AAAs. Many of the 461 
interventions which have been successful in experimental models have been applied prior to or at the 462 
time of AAA induction. However,  treatments are needed for established AAAs in patients.(151) 463 
Recently a number of strategies which were successfully applied in animal models, such as 464 
doxycycline mediated MMP inhibition and use of a mast cell inhibitor, have been reported to be 465 
ineffective at limiting AAA growth in patients.(152, 153) It is currently not clear why previous 466 
promising strategies to limit AAA growth have not been translated to patients, although suggested 467 
reasons include poor design of previous animal studies, inappropriate animal models and ineffective 468 
approaches to inhibiting the pathways that were targeted. Given that patients with AAA usually have 469 
multiple co-morbidities any treatment to limit AAA growth would need to be very safe. Based on the 470 
animal data presented in this review a number of non-toxic antioxidant approaches have potential to 471 
limit AAA, such as vitamin E, vitamin C and polyphenolics (curcumin, quercetin, resveratrol). 472 
Despite the promising experimental studies there are no clinical trial data to suggest that such simple 473 
antioxidant therapies are effective. For example, a clinical trial failed to show any significant 474 
association between vitamin E supplement and the incidence of AAA, although no aortic imaging was 475 
included in this trial.(138) Whether such simple approaches to modifying oxidative stress can achieve 476 
a sustained reduction in aortic oxidative stress is uncertain. Clinical trials to examine the value of 477 

















List of abbreviations 493 
5-LO 5-lipooxygenase 
AAA Abdominal aortic aneurysm 
Ang II angiotensin II 
AP-1 Activator protein-1 
ApoE-/- apolipoprotein E deficient 
CaCl2 Calcium chloride 
cAMP cyclic adenosine monophosphate 
CoCl2 Cobalt chloride 
COX Cyclooxygenase 
CuZnSOD Copper-Zinc SOD 
ECM Extracellular matrix 
EcSOD Extracellular SOD 
eNOS Endothelial NOS 
FLAP 5-lipooxygenase activating protein 
H4B Tetrahydrobiopterin 
HMG-CoA 3-hydroxyl-3-methylglutaryl coenzyme A 
HO Heme oxygenase 
IL-1β interleukin-1β 
iNOS Inducible NOS 
JNK c-Jun N-terminal kinase 
MCP-1 Monocyte chemoattractant protein-1 
MIP Macrophage inflammatory protein 
MMP Matrix metalloproteinase 
MnSOD Manganese SOD 
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NADPH Nicotinamide adenine dinucleotide phosphate 
NF-κB nuclear factor-κB 
nNOS Neuronal NOS 
NO Nitric oxide 
NOS Nitric oxide synthase 
NOX Nicotinamide adenine dinucleotide phosphate oxidase 
NSAID nonsteroidal anti-inflammatory drug 
PGE2 Prostaglandin E2 
ROS Reactive oxygen species 
SOD Superoxide dismutase 
TIMP-1 tissue inhibitor of metalloproteinase-1 
TNFα Tumor necrosis factor α 
TNF-α tumor necrosis factor-α 
TRX Thioredoxin 
VSMC Vascular smooth muscle cells 
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Figure legends 939 
Figure 1 A Schematic diagram showing the critical balance between oxidants and antioxidants 940 
in relation to AAA [modified from [(1)].  941 
Endogenous oxidant systems generate reactive oxygen species (ROS) whilst the antioxidants either 942 
detoxify or scavenge ROS. A shift in the balance towards increased oxidant activity, leads to excess 943 
ROS and resultant oxidative stress. Oxidative stress with associated tissue damage and other pro-944 
aneurysmal factors may result in AAA. 945 
Abbreviations: *may generate ROS, AAA= abdominal aortic aneurysm, COX= cyclooxygenase, 946 
ECM= extracellular matrix, LO= lipoxygenase, HO= heme oxygenase, NOS= nitric oxide synthase, 947 
NOX= nicotinamide adenine dinucleotide phosphate oxidase, ROS= reactive oxygen species, SOD= 948 
superoxide dismutase, TRX= thioredoxin, VSMC= vascular smooth muscle cells, XO= xanthine 949 
oxidase. 950 
 951 
Figure 2 Overview of the mechanism leading to oxidative stress and potential treatments to limit 952 
oxidative stress associated with AAA.  953 
AAA risk factors include smoking, male gender, advanced age and family history. Pro-inflammatory 954 
agents include Ang II. ROS generating enzymes include eNOS, NOX, XO, LO, COX. ROS degrading 955 
systems include SOD and catalase. O2 is converted to O2− by NOX. SOD inactivates O2− forming 956 
H2O2, and catalase converts H2O2 to H2O and O2. Under pro-aneurysmal conditions, H2O2 could be 957 
converted to •OH by the Fenton and/or the Haber-Weiss reactions. In addition, O2− then combines 958 
with NO produced by eNOS to form the highly reactive ONOO-. The increase generation of ROS 959 
within the aorta results in oxidative stress which leads to enhance ACE expression which promotes 960 
Ang II production and resultant positive feedback activation of more pro-oxidant enzymes. Oxidative 961 
stress also promotes mitochondria dysfunction, activates signalling molecules, and potentiates 962 
inflammation. It also increases pro-inflammatory cytokine secretion with resultant recruitment of 963 
effector immune cells, release of proteases, leading to ECM degradation, VSMC apoptosis and 964 
consequent AAA development and progression. Key targets currently under investigation include: 1). 965 
Preventing eNOS uncoupling using vitamins, 2). Preventing the production of O2− using NOX-966 
inhibitors, TRX or genetic approaches, 3). Blocking the COX-2 and/or LO pathways using vitamins 967 
and NSAID, 4). Enhancing the effect of SOD using SOD mimetics, folic acid and polyphenolics, 5). 968 
Applying catalase activators to improve the detoxification of H2O2, 6). Using polyphenolics to inhibit 969 
ROS-induced signalling and 7). Employing vitamins, polyphenolics and NSAID to scavenge ROS and 970 
prevent oxidative stress.  971 
Abbreviations: 5-LO= 5-lipooxygenase, AAA= abdominal aortic aneurysm, ACE= angiotensin 972 
converting enzyme, Ang I= angiotensin I, Ang II= angiotensin II, AP-1= activator protein-1, COX= 973 
cyclooxygenase, ECM= extracellular matrix, eNOS= endothelial nitric oxide synthase, Erk1/2= 974 
extracellular signal-regulated kinase 1/2, Fe2+= ferrous iron, Fe3+= ferric iron, H2O2= hydrogen 975 
peroxide, IL-1β= interleukin-1 beta, JNK= c‑Jun N‑terminal kinase, LO= lipoxygenase, MCP-1= 976 
25 
 
monocyte chemoattractant protein-1, MMP= matrix metalloproteinase, NF-κβ= nuclear factor kappa 977 
beta, NO= nitric oxide, NOS= nitric oxide synthase,  NSAIDS= nonsteroidal anti-inflammatory drugs, 978 
NOX= nicotinamide adenine dinucleotide phosphate oxidase, O2-= superoxide, •OH= hydroxyl 979 
radical, ONOO- = peroxynitrite, ROS= reactive oxygen species, SOD= superoxide dismutase, TNF-980 
α= tumour necrosis factor-α, VSMC= vascular smooth muscle cells, XO= xanthine oxidase. Symbols 981 































Table 1 Overview of studies assessing the lipoxygenase pathway in AAA 1011 
Therapies Key findings AAA model Reference 
BLT1 inhibition 
(genetic). 
Inhibition of the 5-LO metabolite, LTB4 
mediated-inflammation. Decreased MMP-2 
and -9 expression. Decreased inflammatory 









Decreased MMP-9 activity and effector 
immune cell recruitment. 71% (genetic) 
and 54% (pharmacological) reduction in 
aortic dilatation.  
Elastase perfused- 
and Ang II-infused 
Ldlr-/- mouse 
models of AAA. 
(67) 
None. Upregulated 5-LO, FLAP, and LTC4S 
transcripts in aneurysmal aorta compared 
with non-aneurysmal control aortas. 
Human.  (74) 
5-LO inhibition 
genetic deletion). 
Decreased MMP-2 and MIP-1α expression. 
Decreased AAA incidence. 






Diminished macrophage accumulation, 
decreased incidence of AAA when 
administered at the same time as Ang II, 
but no significant effect on AAA size when 
administered 14 days after AAA induction. 
Ang II-infused 
ApoE–/– mouse 





Decreased MMP-2, MMP-9, and ROS 
expression. Reduced AAA formation 
(when administered from the onset of AAA 
induction), and expansion (when 
administered to already established AAAs). 
Combined elastase-
induced and CaCl2-






No significant effect on aortic media 
inflammation or AAA development in 5-
LO deficient mice or mice administered 
FLAP inhibitor (MK-0591). 
Ang II-infused 
ApoE–/– mouse 
model of AAA. 
(73) 
None. No association between 7 single nucleotide 
polymorphisms in ALOX5AP, the gene 




Abbreviations: 5-LO= 5-lipooxygenase, Ang II= angiotensin-II, ApoE–/– = apolipoprotein E-deficient, 1012 
BLT1= leukotriene B4 receptor-1, FLAP= 5-LO activating protein, CaCl2= calcium chloride, Ldlr-/- = 1013 
low density lipoprotein receptor knockout, LTB4= leukotriene B4, LTC4S= leukotriene C4 synthase, 1014 
MIP= macrophage inflammatory protein, MMP== matrix metalloproteinase, ROS= reactive oxygen 1015 
species. 1016 
Table 2 Studies assessing the association of the cyclooxygenase pathway with AAA  1017 
Therapies Key findings AAA model Reference 
COX-2 inhibition 
(pharmacological). 
Decreased incidence and 
severity of AAA. 
Ang II-infused 
mouse model of 
AAA. 




Decreased MCP-1, MIP-1α 
expression. Decreased 
macrophage infiltration. 
Decreased AAA formation. 
Ang II-infused 













Decreased MMP-9 expression 
and decreased AAA 
development. 
Decreased PGE2 and MMP-9 
expression. Decreased 
inflammatory cell infiltration. 
Decreased AAA expansion. 
Elastase-induced rat 
model of AAA. 
(86) 
(87)  (88) 
COX-2 inhibition 
(pharmacological). 
Decreased MMP-9 expression 
but no significant effect on 
AAA expansion. 
Elastase-induced rat 
model of AAA. 
(89) 
None Significant reduction in AAA 
growth in patients on NSAIDS 






Abbreviations: Ang II= angiotensin-II, ApoE–/– = apolipoprotein E-deficient, COX-2= 1019 
cyclooxygenase-2, MCP= monocyte chemoattractant protein, MIP= macrophage inflammatory 1020 
protein, MMP= matrix metalloproteinase, NSAIDS= nonsteroidal anti-inflammatory drugs, PGE2= 1021 










Table 3 Overview of studies assessing the effects of medications known to affect NOS and/or direct 1030 
NOS inhibition in AAA  1031 
Therapies Key findings AAA model Reference 
Simvastatin Decreased MMP-9, MMP-3, and 
NF-κβ expression. Increased 
TIMP-1 expression. Decreased 
AAA formation. 
Elastase-induced 






Simvastatin Decreased macrophage 
infiltration. No significant effect 
on AAA diameter. 
Ang II-infused 
ApoE–/– and Ldlr-/- 





Fenofibrate Decreased inflammatory cell and 
cytokine expression. Decreased 
VSMC apoptosis. Decreased 
AAA development. 
Ang II-infused 
ApoE–/– and Ldlr-/- 






Decreased MMP-9, MMP-2, and 
NO expression. Decreased AAA 
formation. 
CaCl2-induced 
mouse model of 
AAA. 
(18)  
H4B and eNOS 
inhibition (genetic). 
Increased MMP-9, MMP-2 
expression. Increased 
macrophage infiltration. 
Increased AAA formation. Folic 
acid administration blocked the 
AAA promoting effect of H4B 
deficiency. 
Ang II-infused 






Decreased ECM degradation. 
Decreased macrophage 
infiltration. Decreased O2− 
production. Decreased AAA 
expansion. 
Ang II-infused 




Abbreviations: Ang II= angiotensin-II, ApoE–/– = apolipoprotein E-deficient, CaCl2= calcium 1033 
chloride, ECM= extracellular matrix, eNOS= endothelial nitric oxide synthase, H4B= 1034 
tetrahydrobiopterin, iNOS= inducible nitric oxide synthase, Ldlr-/- = low density lipoprotein receptor 1035 
knockout, MMP= matrix metalloproteinase, NF-κβ= nuclear factor kappa beta, NO= nitric oxide, 1036 
29 
 
O2−= superoxide , TIMP-1= tissue inhibitor of matrix metellaoproteinase-1, VSMC= vascular smooth 1037 
muscle cells. 1038 
 1039 
 1040 
Table 4 Overview of studies assessing superoxide dismutase and/or catalase in AAA  1041 




MMP-9, and NF-κβ 
expression. Decreased 
SOD and catalase 
activity. Decreased AAA 
size. 
CaCl2-induced mouse 




Decreased aortic MCP-1, 
and TNF-α expression. 
Decreased macrophage 
infiltration. Increased 
SOD activity. Decreased 
AAA incidence. 
Ang II-infused ApoE–/– 
mouse model of AAA. 
(121) 
None. Higher catalase activity. 
Reduced NF-κβ 
expression. No effect on 
SOD activity and H2O2 
in AAA wall in vitro. 






expansion in rats 
receiving tamoxifen to 
increase catalase 
expression. A catalase 
inhibitor (AT) blocked 
the AAA protective 
effects of tamoxifen. 
Elastase-induced rat 






exhibited increased H2O2 
degradation and 
decreased aortic wall 
remodelling. 
Ang II-infused mouse 












model of AAA. 
 (119) 
Abbreviations: Ang II= angiotensin-II, ApoE–/– = apolipoprotein E-deficient, AT=3-amino-1, 2, 4-1042 
triazole, CaCl2= calcium chloride, H2O2= hydrogen peroxide, MMP== matrix metalloproteinase, 1043 
MnSOD= manganese superoxide dismutase,NF-κβ= nuclear factor kappa beta, SOD= superoxide 1044 
dismutase, TNF-α= tumor necrosis factor-α, VSMC= vascular smooth muscle cells. 1045 
 1046 
 1047 
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